ECCO ESMO 2011 radium-223 Alpharadin media briefing video
The phase 3 ALSYMPCA prostate cancer trial results for radium-223 chloride (Alpharadin) were presented at the recent ECCO ESMO ESTRO 2011 European Multidisciplinary Cancer Congress in Stockholm. This was the highlight of the meeting for me.
There was also exciting data in Breast Cancer (BOLERO-2) that you can read more about on Pharma Strategy Blog.
Alpharadin from Norwegian company, Algeta, is the first new treatment for advanced prostate cancer that not only prolongs overall survival (OS) but delays time to first skeletal related event (SRE) in metastatic castration resistant prostate cancer patients.
Leading physicians at the meeting believe that it will be “practice changing.”
The Alpharadin data may also have an impact on other bone targeted agents in development for prostate cancer such as cabozantinib (XL184).
Sally Church, PhD (who writes the Pharma Strategy Blog) is quoted by “The Street” as saying that “Alpharadin raises the bar for Exelixis. They have to produce overall survival data now.” Overall Survival (OS) remains the primary regulatory endpoint in prostate cancer drug development.
Prostate cancer experts Johann de Bono and Cora Sternberg also mentioned, in presentations at the Stockholm meeting, that in the future it will be increasingly difficult to do placebo controlled trials in Prostate Cancer given the new treatment options available.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
One Response to “ECCO ESMO 2011 radium-223 Alpharadin media briefing video”
[…] Cancer Congress in Stockholm (EMCC 2011), Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-rela…. This is the first time a product in the bone category has shown such a survival benefit – […]
Comments are closed.